# Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma

> **NCT07032129** · PHASE1,PHASE2 · RECRUITING · sponsor: **Essen Biotech** · enrollment: 60 (estimated)

## Conditions studied

- Multiple Myeloma
- Multiple Myeloma in Relapse
- Multiple Myeloma Progression
- Multiple Myeloma, Refractory

## Interventions

- **BIOLOGICAL:** BCMA/GPRC5D CAR-T cells

## Key facts

- **NCT ID:** NCT07032129
- **Lead sponsor:** Essen Biotech
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-29
- **Primary completion:** 2027-12-10
- **Final completion:** 2028-12-28
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07032129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07032129, "Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07032129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*